article thumbnail

IBM sells off large parts of Watson Health business

pharmaphorum

Francisco Partners is picking up a range of databases and analytics tools – including Health Insights, MarketScan, Clinical Development, Social Programme Management, Micromedex and other imaging and radiology tools – for an undisclosed sum estimated to be in the region of $1 billion.

Radiology 111
article thumbnail

Patient Safety and Radiopharmaceuticals Administration: Minimizing Radiation Exposure and Risks

Worldwide Clinical Trials

With radiopharmaceuticals emerging as a diagnostic and therapeutic (theranostics) procedure, many are in the clinical development pipeline and are expected to play a crucial role in the future of healthcare. The goal is to deliver a precise radiation dose to the diseased tissues while minimizing damage to surrounding healthy tissue.

Hormones 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Bayer delivers on medical innovation fueling transformation of pharma business

The Pharma Data

At its annual Pharma Media Day 2022, Bayer presented the latest developments in the ongoing transformation of its pharmaceuticals business, which is aimed at delivering long-term, sustainable business growth by bringing forward new options for patients. “We Re-imagining Radiology.

article thumbnail

Alume Receives SBIR Phase II Grant from the NIH to Support Clinical Trial of ALM-488 to Highlight Nerves in Patients Undergoing Head & Neck Surgery

The Pharma Data

This grant will support Alume’s clinical development of its novel nerve illumination technology in surgery. Alume is a biotechnology company founded in 2017 that is developing nerve-targeted pharmaceutical agents for surgical and therapeutic use. (Alume) announced today that it has been awarded a $2.5M

article thumbnail

Unveiling Potential: Exploring Alpha Emitter Radiopharmaceuticals

XTalks

Advantages of Alpha Emitter Therapy Over the past two decades, the radiological and chemical properties of alpha emitting isotopes have regained prominence in medical physics. Alpha particle therapy represents a significant advancement in cancer treatment, reflecting the growing trend in oncology towards personalized and precision medicine.

DNA 66
article thumbnail

Bayer acquires Noria and PSMA Therapeutics to expand portfolio in prostate cancer

The Pharma Data

Noria was founded by Dr. John Babich, Chief, Radiopharmaceutical Sciences in Radiology at Weill Cornell Medicine. Xofigo is currently under further evaluation in a broad clinical development program in prostate cancer and beyond.

article thumbnail

Evusheld long-acting antibody combination approved in the EU for pre-exposure prophylaxis (prevention) of COVID-19 in a broad population

The Pharma Data

AstraZeneca AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. W911QY-21-9-0001.